| Literature DB >> 32547472 |
Megan E Schliep1,2, Laura Kasparian3, Olga Kaminski3, Carla Tierney-Hendricks1,2, Esther Ayuk2, Lynne Brady Wagner2, Semra Koymen3, Sofia Vallila-Rohter1,3.
Abstract
The research to practice gap is a significant problem across all disciplines of healthcare. A major challenge associated with the adoption of evidence into routine clinical care is the disconnect between findings that are identified in a controlled research setting, and the needs and challenges of a real-world clinical practice setting. Implementation Science, which is the study of methods to promote research into clinical practice, provides frameworks to promote the translation of findings into practice. To begin to bridge the research-practice gap in assessing recovery in individuals with aphasia in the acute phases of recovery following stroke, clinicians in an acute care hospital and an inpatient rehabilitation hospital followed an implementation science framework to select and implement a standardized language assessment to evaluate early changes in language performance across multiple timepoints. Using a secure online database to track patient data and language metrics, clinically-accessible information was examined to identify predictors of recovery in the acute phases of stroke. We report on the feasibility of implementing such standardized assessments into routine clinical care via measures of adherence. We also report on initial analyses of the data within the database that provide insights into the opportunities to track change. This initiative highlights the feasibility of collecting clinical data using a standardized assessment measure across acute and inpatient rehabilitation care settings. Practice-based evidence may inform future research by contributing pilot data and systematic observations that may lead to the development of empirical studies, which can then feed back into clinical practice.Entities:
Keywords: acute care; aphasia; implementation science; rehabilitation; standardized assessment; stroke recovery
Year: 2020 PMID: 32547472 PMCID: PMC7278284 DOI: 10.3389/fneur.2020.00412
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Fourteen critical steps of quality implementation according to the Quality Implementation Framework (QIF) established by Meyers et al. (22).
Figure 2Summary of QIF Process at Spaulding Rehabilitation Hospital. Implementation 1.0 included the WAB Bedside, as well as four subtests from the CLQT (Clock Drawing, Symbol Cancellation, Design Memory, Design Generation). Assessment of reading and writing skills was formalized to improve consistency of administration. The assessment measure was administered to all patients with CVA admitted to the Stroke Program. Implementation 2.0 included the addition of a screening tool, administration of the full WAB (rather than WAB Bedside) upon admission for individuals with L MCA stroke, and re-evaluation via the WAB Bedside at 10–14 days post admission. Implementation 3.0 included training and expansion for assessment administration by all clinicians, including full-time employees and per diem weekend staff, as well as expansion to CVA admissions hospital-wide (rather than just those admitted to the Stroke Program).
Adherence to Spaulding Rehabilitation Assessment Protocol (percentages).
| Language measure (WAB-R) | 33% | 31% | 2% | 27% | ||
| Cognitive-linguistic measure (CLQT) | 68% | 61% | 35% | 52% | ||
| Language measure (WAB-bedside) | 50% | 40% | 31% | 37% | ||
| Language measure (WAB-bedside) | 38% | 22% | 5% | 16% | ||
| Cognitive-linguistic measure (CLQT) | 25% | 14% | 35% | 52% | ||
| Language measure (WAB-R) | 9% | 8% | 2% | 6% | ||
| Language measure (WAB-bedside) | 51% | 53% | 28% | 43% | ||
| Cognitive-linguistic measures (CLQT) | 63% | 67% | 31% | 52% | ||
| Language measure (WAB-R) | 1% | 2% | 0% | 1% | ||
| Language measure (WAB-bedside) | 20% | 8% | 0% | 4% | ||
| Cognitive-linguistic measure (CLQT) | 28% | 13% | 5% | 9% | ||
| Language measure (WAB-R) | 2% | 1% | 0% | <1% | ||
TOTAL Hospital Admissions includes Stroke and Rehabilitation Program Admissions.
Demographic and stroke-related information for eligible cases.
| 1 | 70–74 | 1 | Posterior | 4 | B | 85 | Anomic | 7 | F | 98.4 | No Aphasia | ||||
| 2 | 85–89 | 29 | Both | 1 | B | 80 | Anomic | 5 | F | 94.6 | Anomic | ||||
| 3 | 90–94 | 20 | Posterior | 3 | B | 40.8 | Conduction | 6 | F | 55.5 | Conduction | ||||
| 4 | 55–59 | 4 | Both | 1 | B | 38.3 | Broca's | 8 | F | 79.4 | TCM | ||||
| 5 | 65–69 | 15 | Both | 2 | B | 36.7 | Broca's | 3 | F | 37.5 | Broca's | ||||
| 6 | 80–84 | 4 | Both | 1 | B | 31.7 | Wernicke's | 6 | F | 45.2 | Wernicke's | ||||
| 7 | 80–84 | 4 | Both | 0 | B | 24.2 | Wernicke's | 5 | B | Fluent | |||||
| 8 | 40–44 | 6 | Both | 1 | B | 20 | Broca's | 5 | B | Broca's | |||||
| 9 | 80–84 | 11 | Both | 3 | B | 19.2 | Broca's | 4 | F | 11.9 | Broca's | ||||
| 10 | 70–74 | 5 | Anterior | 2 | B | 55.8 | TCM | 5 | F | 78 | Anomic | 14 | B | 90.8 | Anomic |
| 11 | 80–84 | 19 | Both | 4 | B | 48.3 | Broca's | 10 | F | 68.5 | TCM | 37 | B | 96.7 | No Aphasia |
| 12 | 80–84 | – | Posterior | 1 | B | 41.7 | Wernicke's | 4 | B | 40 | Wernicke's | 23 | B | 26.7 | Wernicke's |
| 13 | 65–69 | – | Both | 14 | B | 39.2 | Broca's | 16 | F | 34.4 | Broca's | 37 | F | 43.8 | Broca's |
| 14 | 85–89 | 16 | Anterior | 6 | B | 19.2 | Broca's | 14 | F | 18.6 | Broca's | 33 | F | Broca's | |
| 15 | 70–74 | 22 | Both | 14 | B | 10 | Global | 16 | F | 7.2 | Broca's | 30 | B | 15 | Broca's |
| 16 | 55–59 | 29 | Both | 7 | B | Global | 16 | F | 11.3 | Global | 29 | B | 34.2 | Broca's | |
| 17 | 75–79 | 8 | Anterior | 5 | F | 80.8 | Anomic | 15 | B | 91.7 | Anomic | ||||
| 18 | 50–54 | 13 | 6 | F | 79.5 | TCM | 17 | F | 94.3 | Anomic | |||||
| 19 | 50–54 | 18 | Anterior | 4 | B | 78.3 | Anomic | 22 | B | 97.5 | Anomic | ||||
| 20 | 45–49 | 17 | 19 | B | 75.8 | TCS | 34 | B | 76.7 | Conduction | |||||
| 21 | 50–54 | 7 | Anterior | 14 | B | 67.5 | Anomic | 31 | B | 85 | Anomic | ||||
| 22 | 70–74 | 3 | Anterior | 14 | B | 61.7 | Anomic | 27 | B | 80.8 | Anomic | ||||
| 23 | 85–89 | 7 | 12 | F | 61.2 | Broca's | 28 | B | 86.7 | Anomic | |||||
| 24 | 65–69 | 9 | 11 | F | 59.1 | TCS | 34 | B | 91.7 | Anomic | |||||
| 25 | 65–69 | – | 22 | F | 58.9 | TCM | 41 | F | 77.6 | Anomic | |||||
| 26 | 80–84 | – | Both | 6 | F | 56.6 | Wernicke's | 18 | F | 70.3 | TCS | ||||
| 27 | 40–44 | 10 | Anterior | 20 | F | 48.9 | TCM | 28 | B | 53.3 | Broca's | ||||
| 28 | 60–64 | 6 | 34 | F | 32.4 | Wernicke's | 57 | F | 35.1 | Wernicke's | |||||
| 29 | 75–79 | 2 | Anterior | 5 | F | 27.2 | Broca's | 17 | B | 57.5 | Broca's | ||||
| 30 | 25–29 | 22 | 17 | B | 25 | Broca's | 35 | B | 53.3 | Broca's | |||||
| 31 | 80–84 | 8 | Both | 8 | B | 23.3 | Wernicke's | 20 | B | 24.2 | Wernicke's | ||||
| 32 | 55–59 | 22 | Both | 8 | F | 22 | Global | 20 | F | 35.1 | TC-Mixed | ||||
| 33 | 55–59 | 18 | 16 | F | 12.1 | Global | 50 | F | 18 | Global | |||||
| 34 | 90–94 | – | 10 | F | 9.7 | Broca's | 24 | B | 20 | Broca's | |||||
| 35 | 45–49 | – | 9 | F | 7.5 | Global | 19 | B | 32.5 | Broca's | |||||
| 36 | 75–79 | 18 | 5 | F | 0 | Global | 25 | F | 34.7 | Global | |||||
| 37 | 40–44 | 25 | 17 | F | Global | 30 | B | 38.3 | Broca's | ||||||
Age range rather than specific age is reported and sex is omitted from this table for confidentiality purposes. Lesion Location information is reported based on the radiology report from the medical record; in cases where the radiology report was not available, location was obtained from the clinical note and is reported in italics—this information is included for information purposes only and is not included in statistical analyses. Severity ratings for Aphasia Quotient (AQ) are as follows: 0–25 Severe-Profound; 26–50 Severe, 51–75 Moderate; 76+ Mild. “B” denotes WAB Bedside version; “F” denotes WAB Full version.
Denotes participant was unable to pass screener to yield AQ;
Denotes missing subdomain scores, impacting calculation of AQ.
Correlation matrix between continuous variables of interest.
| Age | 1 | 0.46 | −0.27 | 0.43 | −0.27 | −0.34 |
| NIHSS | 1 | −0.69 | 0.87 | −0.66 | −0.46 | |
| BWH AQ | 1 | −0.96 | 1 | 0.94 | ||
| Days to SRH Eval 1 | 1 | −0.95 | −0.84 | |||
| SRH Eval 1 AQ | 1 | 0.96 | ||||
| SRH Eval 2 AQ | 1 |
Shading reflects the relative strength of correlations, with darker shading indicating a stronger correlation.
Figure 3WAB AQ proportion of maximal recovery from SRH initial evaluation to re-evaluation as a function of time (days) between evaluations.
Figure 4WAB AQ proportion of maximal recovery from SRH initial evaluation to re-evaluation as a function of severity at initial assessment.